Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum

Background and Objectives Studies are sparse regarding the association between the informant-reported subjective memory decline (informant report) and Alzheimer disease (AD) biomarkers. This study thus aimed at determining the clinical relevance of the informant report throughout the AD clinical continuum, by assessing its specific relationships with amyloid deposition, cognition, and neurodegeneration. Methods Participants from the Imagerie Multimodale de la maladie d'Alzheimer 'a un stade Precoce (IMAP+) primary cohort and the Alzheimer Disease Neuroimaging Initiative (ADNI) replication cohort were included; all underwent multimodal neuroimaging and neuropsychological assessments. Follow-up data of IMAP+ participants over up to 36 months were also used for longitudinal analyses. The informant report was measured with the Cognitive Difficulties Scale (IMAP+) and Everyday Cognition (ADNI). General linear models were used to assess the cross-sectional associations between the informant report and amyloid-PET, cognitive performances, and neurodegeneration (atrophy and hypometabolism) in Alzheimer signature areas; while longitudinal links were assessed in IMAP+ with linear mixed-effects models. Results A total of 110 IMAP+ participants were included, including 32 cognitively unimpaired older individuals (controls, age: 70.91 +/- 6.57 years, female: 50%), 25 patients with subjective cognitive decline (SCD, 65.88 +/- 6.64, 40%), 35 with mild cognitive impairment (MCI, 72.49 +/- 7.5, 34%), and 18 with Alzheimer-type dementia (AD dementia, 68.17 +/- 8.59, 28%). Seven hundred thirty-one ADNI participants were included, including 157 controls (74.21 +/- 5.95, 55%), 84 with SCD (72.00 +/- 5.41, 63%), 369 with MCI (71.84 +/- 7.4, 44%), and 121 with AD dementia (74.29 +/- 7.75, 40%). In IMAP+, a higher informant report strongly correlated to greater amyloid-PET, specifically in patients with MCI (beta = 0.48, p = 0.003), and to lower cognitive performance in patients with SCD (global cognition, beta = -0.41, p = 0.04) and MCI (memory, beta = -0.37, p = 0.03). Findings in patients with MCI were replicated in the ADNI (amyloid-PET, beta = 0.25, p < 0.001; memory, beta = -0.22, p < 0.001) and extended to neurodegeneration in AD signature areas (beta = -0.2, p < 0.001). Longitudinal analyses in IMAP+ showed links with global cognitive decline over time in patients with MCI (estimate -0.74, SE 0.26, p = 0.005) and SCD (estimate -0.36, SE 0.26, p = 0.02) where a higher baseline informant report also predicted an increased amyloid-PET over time (estimate 0.008, SE 0.003, p = 0.02). Discussion Altogether, our findings suggest that the informant report is particularly relevant in patients with MCI where it strongly relates to higher amyloid-PET, indicative of impairment due to AD.

Automated summary

This study aimed to assess the association between informant-reported subjective memory decline and Alzheimer disease biomarkers. The results showed a strong correlation between the informant report and higher amyloid deposition as well as lower cognitive performance in patients with mild cognitive impairment.